argenx announces Annual General Meeting of Shareholders 28 April 2016

March 16, 2016

Breda, the Netherlands – arGEN-X N.V. (Euronext Brussels: ARGX, hereinafter: the "Company"), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announces that an annual general meeting of shareholders will be held on Thursday 28 April 2016. 

The shareholders and all other persons with meeting rights are invited to attend the annual general meeting of shareholders, to be held at 9:00 AM on Thursday 28 April 2016 at Sheraton Amsterdam Schiphol Airport, Schiphol Boulevard 701, 1118 BG Schiphol, the Netherlands.

The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting and regarding the e-voting system) is available on the Company's website www.argenx.com.

Agenda

The full agenda for the meeting as well as all ancillary documents relevant for the meeting are available via the company website, and are also available for inspection at the Company's offices. A free copy thereof may also be obtained by e-mailing annualmeeting@argenx.com.

Next to recurrent items on the agenda such as the discussion and adoption of the 2015 Annual Accounts, discharge of the directors for their duties performed in 2015 and the authorisation of the board of directors to issue shares and to limit or exclude pre-emptive rights in relation thereto, the following is, amongst other, proposed:

  • Appointment of P. Klein as non-executive director to the board of directors of the Company;
  • Approval of the amended argenx option plan;
  • Approval of a new remuneration policy relating to the Company's statutory directors ; and
  • Appointment of Deloitte Accountants B.V. for the 2016 financial year.

About argenx

argenx combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey.